Novo Nordisk's GLP-1 for Type II diabetes approved for first-line treatment

Rybelsus, Novo Nordisk’s GLP-1 also known as semaglutide, snagged a label update from the FDA, allowing patients to take it as a first-line treatment for Type II diabetes in 7 or 14 mg, the company announced.